The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety, pharmacokinetics, and clinical activity of OBI-3424, an AKR1C3-activated prodrug, in patients with advanced or metastatic solid tumors: A phase 1 dose-escalation study.
 
Apostolia Maria Tsimberidou
Consulting or Advisory Role - Diaccurate; Vincerx Pharma
Research Funding - Agenus (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); Novocure (Inst); OBI Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Tempus (Inst); Tvardi Therapeutics (Inst)
Travel, Accommodations, Expenses - Japanese Society of Clinical Oncology
 
Claire F. Verschraegen
No Relationships to Disclose
 
Pei Hsu
Employment - OBI Pharma
Stock and Other Ownership Interests - OBI Pharma
Travel, Accommodations, Expenses - OBI Pharma
 
Tillman E. Pearce
Employment - OBI Pharma
Leadership - OBI Pharma
Stock and Other Ownership Interests - OBI Pharma
Travel, Accommodations, Expenses - OBI Pharma